|
Indication & Dosage |
|
|
Oral |
TREATMENT OF PSYCHOSES |
Adult:
Initially, 2.5-10 mg daily in 2-3 divided doses, increased according to reponse. Maintenance: 1-5 mg daily. |
Max Dosage: Adult: 20 mg/day. Elderly: 10 mg/day. |
|
Oral |
MANIA |
Adult:
Initially, 2.5-10 mg daily in 2-3 divided doses, increased according to reponse. Maintenance: 1-5 mg daily. |
Max Dosage: Adult: 20 mg/day. Elderly: 10 mg/day. |
|
Oral |
SCHIZOPHRENIA |
Adult:
Initially, 2.5-10 mg daily in 2-3 divided doses, increased according to reponse. Maintenance: 1-5 mg daily. |
Max Dosage: Adult: 20 mg/day. Elderly: 10 mg/day. |
|
Oral |
SHORT-TERM ADJUNCTIVE MANAGEMENT OF SEVERE ANXIETY OR BEHAVIORAL DISTURBANCES |
Adult:
1 mg bid increased to 2 mg bid if necessary. |
|
Intramuscular |
TREATMENT OF PSYCHOSES |
Adult:
As decanoate: Initially, 12.5 mg adjusted according to response. Maintenance: 12.5-100 mg at intervals of 2-6 wk. For doses >50 mg, increments should be made slowly in steps of 12.5 mg. The enantate ester can be given in similar doses at intervals of 1-3 wk. |
Max Dosage: 6.25 mg adjusted according to response. |
|
Intramuscular |
MANIA |
Adult:
As decanoate: Initially, 12.5 mg adjusted according to response. Maintenance: 12.5-100 mg at intervals of 2-6 wk. For doses >50 mg, increments should be made slowly in steps of 12.5 mg. The enantate ester can be given in similar doses at intervals of 1-3 wk. |
Max Dosage: 6.25 mg adjusted according to response. |
|
Intramuscular |
SCHIZOPHRENIA |
Adult:
As decanoate: Initially, 12.5 mg adjusted according to response. Maintenance: 12.5-100 mg at intervals of 2-6 wk. For doses >50 mg, increments should be made slowly in steps of 12.5 mg. The enantate ester can be given in similar doses at intervals of 1-3 wk. |
Max Dosage: 6.25 mg adjusted according to response. |
|
|
|
Administration |
May be taken with or without food. |
|
|
Precautions |
Presence of convulsive disorders; hepatic, renal, cerebrovascular, resp and CV diseases; elderly or debilitated patients. May elevate prolactin levels which may persist after chronic admin. May exacerbate depression. Closed-angle glaucoma. History of jaundice, parkinsonism, diabetes mellitus, hypothyroidism, myasthenia gravis, paralytic ileus, prostatic hyperplasia or urinary retention. Regular eye examinations in patients receiving long term therapy. Avoid direct sunlight exposure. |
|
|
Potentially Life-threatening
Adverse Drug Reactions |
Tardive dyskinesia, sedation, mental confusion; hypotension; hyperprolactinaemia leading to galactorrhoea and amenorrhoea in women; loss of libido, impotence and sterility in males. Allergic reactions, cholestatic jaundice, corneal and lens deposits, skin pigmentation. |
|
|
Adverse Drug Reactions |
Agranulocytosis; neuroleptic malignant syndrome. |
|
|
Interactions |
Additive CNS depressant effects with alcohol, barbiturates, hypnotics, sedatives, opiates and antihistamines. Reduces antihypertensive effects of guanethidine, methyldopa and clonidine. Lithium toxicity. Reduced bioavailability with antacids. Increased risk of arrhythmia when used with drugs that prolong QT interval. May cause electrolyte disturbance when used with diuretics. |
|
|
|
|